CreatorsPublishersAdvertisers
View more in
Diseases & Treatments

Dr. Rampal on Selecting Among Available JAK Inhibitors in Myelofibrosis

onclive.com
 2021-07-22

Raajit K. Rampal, MD, PhD, discusses considerations for selecting among the JAK inhibitors ruxolitinib and fedratinib in the treatment of patients with myelofibrosis. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses considerations for selecting among the JAK inhibitors ruxolitinib (Jakafi) and fedratinib (Inrebic) in the treatment of patients with myelofibrosis.

www.onclive.com

Comments / 0

Comments / 0